ES2179523T3 - Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados. - Google Patents

Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados.

Info

Publication number
ES2179523T3
ES2179523T3 ES98935892T ES98935892T ES2179523T3 ES 2179523 T3 ES2179523 T3 ES 2179523T3 ES 98935892 T ES98935892 T ES 98935892T ES 98935892 T ES98935892 T ES 98935892T ES 2179523 T3 ES2179523 T3 ES 2179523T3
Authority
ES
Spain
Prior art keywords
antihistamine
biodisponibility
fexofenadine
derivatives
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98935892T
Other languages
English (en)
Inventor
Kin-Kai Hwang
Dennis H Giesing
Gail H Hurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2179523T3 publication Critical patent/ES2179523T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una combinación para mejorar la biodisponibilidad de una antihistamina de piperidinoalcanol de la siguiente fórmula I en la que R es hidrógeno o un grupo alquilo de C1-C6, o una de sus sales farmacéuticamente aceptables o de sus isómeros ópticos individuales, que comprende una cantidad antihistamínica efectiva de dicha antihistamina de piperidinoalcanol y un cantidad efectiva inhibidora de la p-glicoproteína de un inhibidor de p-glicoproteína, en una forma de dosificación adecuada para administración conjunta.
ES98935892T 1997-08-14 1998-07-21 Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados. Expired - Lifetime ES2179523T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14

Publications (1)

Publication Number Publication Date
ES2179523T3 true ES2179523T3 (es) 2003-01-16

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98935892T Expired - Lifetime ES2179523T3 (es) 1997-08-14 1998-07-21 Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados.

Country Status (30)

Country Link
EP (1) EP1003528B1 (es)
JP (1) JP4295913B2 (es)
KR (1) KR100522985B1 (es)
CN (1) CN1143680C (es)
AR (1) AR018505A1 (es)
AT (1) ATE224721T1 (es)
AU (1) AU725965C (es)
BR (1) BR9811937A (es)
CA (1) CA2301267C (es)
CZ (1) CZ293666B6 (es)
DE (1) DE69808303T2 (es)
DK (1) DK1003528T3 (es)
EE (1) EE04263B1 (es)
ES (1) ES2179523T3 (es)
HK (1) HK1025901A1 (es)
HU (1) HU226823B1 (es)
ID (1) ID24463A (es)
IL (1) IL134521A (es)
NO (1) NO325148B1 (es)
NZ (1) NZ502133A (es)
OA (1) OA11287A (es)
PL (1) PL191607B1 (es)
PT (1) PT1003528E (es)
RU (1) RU2197967C2 (es)
SK (1) SK283868B6 (es)
TR (1) TR200000419T2 (es)
TW (1) TWI240633B (es)
UA (1) UA64765C2 (es)
WO (1) WO1999008690A1 (es)
ZA (1) ZA987221B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
ATE238773T1 (de) * 1997-08-26 2003-05-15 Aventis Pharma Inc Arzneimittel für die kombination piperidinoalkanol-dekongestivum
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
BR0306329A (pt) * 2002-05-29 2005-04-26 Aventis Pharmaceuticals Holdin Método de tratamento de asma
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
BR112013029778A2 (pt) 2011-05-20 2017-01-17 Aventis Pharma Inc composição farmacêutica que compreende fexofenadina
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO1996040792A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
EE200000069A (et) 2000-10-16
PL338579A1 (en) 2000-11-06
CA2301267A1 (en) 1999-02-25
CZ2000522A3 (cs) 2000-09-13
ZA987221B (en) 1999-02-15
CZ293666B6 (cs) 2004-06-16
RU2197967C2 (ru) 2003-02-10
PL191607B1 (pl) 2006-06-30
CN1267221A (zh) 2000-09-20
HU226823B1 (hu) 2009-11-30
IL134521A0 (en) 2001-04-30
AR018505A1 (es) 2001-11-28
NO20000706D0 (no) 2000-02-11
DK1003528T3 (da) 2003-02-03
WO1999008690A1 (en) 1999-02-25
BR9811937A (pt) 2000-09-05
NZ502133A (en) 2002-03-28
JP4295913B2 (ja) 2009-07-15
KR100522985B1 (ko) 2005-10-21
CA2301267C (en) 2004-07-13
AU725965B2 (en) 2000-10-26
HUP0003189A2 (en) 2001-03-28
AU725965C (en) 2004-04-22
TR200000419T2 (tr) 2000-09-21
IL134521A (en) 2005-07-25
ATE224721T1 (de) 2002-10-15
AU8505098A (en) 1999-03-08
HUP0003189A3 (en) 2001-04-28
ID24463A (id) 2000-07-20
UA64765C2 (uk) 2004-03-15
HK1025901A1 (en) 2000-12-01
CN1143680C (zh) 2004-03-31
EP1003528B1 (en) 2002-09-25
EP1003528A1 (en) 2000-05-31
OA11287A (en) 2003-10-22
SK283868B6 (sk) 2004-03-02
SK1842000A3 (en) 2000-08-14
EE04263B1 (et) 2004-04-15
TWI240633B (en) 2005-10-01
KR20010022845A (ko) 2001-03-26
DE69808303T2 (de) 2003-05-22
PT1003528E (pt) 2003-02-28
NO20000706L (no) 2000-04-13
JP2001515041A (ja) 2001-09-18
DE69808303D1 (de) 2002-10-31
NO325148B1 (no) 2008-02-11

Similar Documents

Publication Publication Date Title
ES2179523T3 (es) Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados.
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
GT199900148A (es) Desnaturalizantes para las sales aminas simpaticomimeticas.
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
ATE297203T1 (de) Antithrombotische mitteln
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
AR008782A1 (es) Una composicion farmaceutica antitrombotica y antiaterogena, y sus usos
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
PT1105105E (pt) Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ES2194933T3 (es) Inhibidores de la agregacion plaquetaria.
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
ES2192263T3 (es) Derivados de benzo(c)quinolizina, su preparacion y empleo como inhibidores de 5-alfa-reductasas.
CO4750811A1 (es) Acidos 3-sustituidos-2-aminobiciclo [3.1.0] hexano-2,6- dicarboxilicos
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO4950550A1 (es) Procedimiento
ES2182090T3 (es) Nuevos derivados de pirrol.
CO4970804A1 (es) Nuevos derivados de la vitamina d3